retatrutide triple agonist glp-1 gip glucagon phase 2 results Eli Lilly's shows promising weight loss in 3 trial Diagram showing the mechanism of

340-OR: LY3437943 (LY), a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment Multi-receptor incretin agonists are being developed with the goal of treating various metabolic diseases

The Congressional Budget Office projects states will receive $58 billion less from the federal government in fiscal year 2024 than they did in the prior fiscal year

But herbal tea, broth, and water-rich foods like cucumber, watermelon, and celery all contribute

What Are GLP-1 Receptor Agonists

The table below summarizes average weight loss outcomes and key clinical characteristics from major randomized controlled trials and real-world evidence

But "modest effects in animal studies" is an enormous distance from "clinically meaningful weight loss in humans." The gap between preclinical promise and proven human results is where most supplement claims fall apart